Holen Sie sich die Stockscreener-App
2.77
6.10%
-0.18
Handel nachbörslich:
2.80
0.03
+1.08%
Schlusskurs vom Vortag:
$2.95
Offen:
$2.79
24-Stunden-Volumen:
109.21K
Relative Volume:
0.11
Marktkapitalisierung:
$3.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.32M
KGV:
-3.8472
EPS:
-0.72
Netto-Cashflow:
$-7.30M
1W Leistung:
+36.45%
1M Leistung:
+28.84%
6M Leistung:
-51.09%
1J Leistung:
+14.70%
1-Tages-Spanne:
$2.74
$2.99
1-Wochen-Bereich:
$2.4501
$6.39
52-Wochen-Spanne:
$1.835
$71.85
Tharimmune Inc Stock (THAR) Company Profile
Firmenname
Tharimmune Inc
Sektor
Branche
Telefon
302-743-2995
Adresse
1200 ROUTE 22 EAST, BRIDGEWATER
Tharimmune Inc Aktie (THAR) Neueste Nachrichten
Tharimmune Announces Upcoming Conference Presentations - StockTitan
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
What's Going On With Tharimmune Shares Wednesday? - MSN
S&P 500 Edges Lower; US Crude Oil Inventories Fall - MSN
New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback" - MSN
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Coversee more stocks inside... - openPR
Tharimmune (THAR) Stock Rallies After Positive EMA Feedback Boosts Confidence - Stocks Telegraph
Tharimmune receives regulatory feedback from EMA for TH104 program - TipRanks
Tharimmune secures EMA feedback on pruritus drug trial - Investing.com
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - StockTitan
TH104 trial shows promise for liver disease-related itch relief By Investing.com - Investing.com South Africa
TH104 trial shows promise for liver disease-related itch relief - Investing.com
Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting - TipRanks
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Milton Daily Standard
Tharimmune CEO Randy Milby buys $5.2k in company stock - Investing.com India
Tharimmune CEO Randy Milby buys $5.2k in company stock By Investing.com - Investing.com Australia
Tharimmune COO acquires $9,650 in company stock - Investing.com
Tharimmune COO acquires $9,650 in company stock By Investing.com - Investing.com UK
Biohaven aims to raise $250M; Activist investor’s stake in Galapagos exceeds 10% - Endpoints News
Tharimmune Announces Intent to Acquire Intract Pharma - TipRanks
Tharimmune signs nonbinding LOI to merge with Intract Pharma - TipRanks
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - StockTitan
Hillstream Biopharma stock plunges to 52-week low of $2.52 - Investing.com India
Tharimmune Expands Immunology Pipeline with Intract License - TipRanks
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July - Defense World
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardChannel3000.com - Channel3000.com - WISC-TV3
Tharimmune adds David Clarke as Strategic Advisor - Investing.com
Tharimmune launches new website amid continuing discussions wtih FDA - TipRanks
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - StockTitan
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 - StockTitan
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World
Tharimmune names industry veteran Haimovitz as strategic advisor - Investing.com
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor - StockTitan
Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com Australia
Tharimmune to sell 659,545 shares at $3.16 in private placementTipRanks.com - TipRanks
Tharimmune raises $2.08 million in private placement - Investing.com India
Tharimmune Announces $2.08 Million Private Placement | THAR Stock News - StockTitan
Tharimmune Announces $2.08 Million Private Placement - StockTitan
Tharimmune announces Type C meeting with FDA for Phase 2 TH104 programTipRanks.com - TipRanks
THAR: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
FDA nods to Tharimmune's Phase 2 itch relief trial plan By Investing.com - Investing.com
FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com India
Finanzdaten der Tharimmune Inc-Aktie (THAR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):